NCT05749861View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 22, 2023

Primary Completion Date

June 7, 2023

Study Completion Date

July 18, 2023

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-348(5)

QD, PO

DRUG

CKD-828, D097, D337

QD, PO

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY